Aethlon Medical, Inc. (AEMD) Financial Ratios

Aethlon Medical, Inc. (AEMD) has an ST Score of 43.9 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate AEMD a Hold, with a price target of $1.50 (-77.8% vs the current price). Our ST Score grades it C (43.9/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B, Profitability C-, Financial Strength B+, Momentum C, Growth B+, Forecast D.

Aethlon Medical, Inc. (AEMD) earns a valuation grade of B, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Aethlon Medical, Inc. (AEMD) earns a growth grade of B+, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Aethlon Medical, Inc. (AEMD) earns a profitability grade of C-, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Aethlon Medical, Inc. (AEMD) earns a financial strength grade of B+, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Aethlon Medical, Inc. (AEMD) is $1.50 from 3 analysts, which is -77.8% versus the recent price of $6.77.

Aethlon Medical, Inc. (AEMD) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.